BioSpace News Archive

PTC Therapeutics, Inc. announced that on June 11, 2021 it approved non-statutory stock options to purchase an aggregate of 118,350 shares of its common stock and 30,835 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 66 new employees.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced publication of its peer-reviewed study in the Journal of Investigative Dermatology (JID) Innovations, addressing the potential benefit of MIMEDX Purion processed dehydrated human amnion/chorion membrane (dHACM) to combat complications stemming from excessive fibrosis,

Braeburn announces that today the New Drug Application (NDA) for BRIXADI was resubmitted to the U.S. Food and Drug Administration (FDA).

Mallinckrodt today announced that the U.S. Food and Drug Administration (FDA) has approved StrataGraft

Commercial availability of superior cancer drugs, growing caseload of leukemia, and extensive R&D activities in oncology are some key factors driving market revenue growth.

Government initiatives and investments by key players to develop advanced tests and kits for detecting Zika virus are key factors fueling global market growth.

Viva Biotech declared that Totient, one of its portfolio companies, has been acquired by AbSci, a synthetic biology company unlocking the potential of proteins as next-generation therapeutics.

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the development of the investigational Synthetic Biotic medicine™ SYNB8802 for the treatment of Enteric Hyperoxaluria and on SYNB1934,

JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the appointment of Nicholas E. Goeders, Ph.D. to its Scientific Advisory Board (SAB)

Emmaus Life Sciences, Inc. (OTC: EMMA), announced today it has received confirmation from the Swiss Agency for Therapeutic Products (Swissmedic) of Emmaus’ application for Marketing Authorization (MA) for Endari® in Switzerland.